Sarepta Therapeutics (SRPT) Free Cash Flow (2010 - 2026)

Sarepta Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$204.8 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 67.35% year-over-year to -$204.8 million in Q1 2026; TTM through Mar 2026 was $114.9 million, a 116.52% increase from a year earlier, with the FY2025 full-year figure at -$307.5 million, up 10.3% from the prior year.
• Free Cash Flow eased to -$204.8 million in Q1 2026 per SRPT's latest filing, from $127.6 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $229.5 million in Q2 2025 and bottomed at -$627.1 million in Q1 2025.
• The 5-year median for Free Cash Flow is -$100.4 million (2022), against an average of -$105.2 million.
• Across the five-year window, Free Cash Flow sank 218.27% in 2022 and jumped 1713.64% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$100.4 million in 2022, then rose by 26.57% to -$73.7 million in 2023, then surged by 173.23% to $54.0 million in 2024, then jumped by 136.48% to $127.6 million in 2025, then tumbled by 260.45% to -$204.8 million in 2026.
• Per Business Quant, the three latest SRPT Free Cash Flow figures stand at -$204.8 million (Q1 2026), $127.6 million (Q4 2025), and -$37.5 million (Q3 2025).